These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
110 related articles for article (PubMed ID: 1906724)
1. In vivo distribution and cytokine gene expression by enriched mouse LAK effector cells. Futami H; Pilaro AM; Gruys ME; Back TC; Young HA; Wiltrout RH Biotherapy; 1991; 3(3):219-32. PubMed ID: 1906724 [TBL] [Abstract][Full Text] [Related]
2. Interactive effects of alpha-interferon A/D and interleukin 2 on murine lymphokine-activated killer activity: analysis at the effector and precursor level. Chikkala NF; Lewis I; Ulchaker J; Stanley J; Tubbs R; Finke JH Cancer Res; 1990 Feb; 50(4):1176-82. PubMed ID: 2297766 [TBL] [Abstract][Full Text] [Related]
3. Decreased interleukin-15 from activated cord versus adult peripheral blood mononuclear cells and the effect of interleukin-15 in upregulating antitumor immune activity and cytokine production in cord blood. Qian JX; Lee SM; Suen Y; Knoppel E; van de Ven C; Cairo MS Blood; 1997 Oct; 90(8):3106-17. PubMed ID: 9376592 [TBL] [Abstract][Full Text] [Related]
4. Tissue distribution and tumor localization of effector cells in adoptive immunotherapy of cancer. Basse PH APMIS Suppl; 1995; 55():1-28. PubMed ID: 8534522 [TBL] [Abstract][Full Text] [Related]
5. In vivo treatment with interferon causes augmentation of IL-2 induced lymphokine-activated killer cells in the organs of mice. Puri RK; Leland P Clin Exp Immunol; 1991 Aug; 85(2):317-25. PubMed ID: 1713814 [TBL] [Abstract][Full Text] [Related]
6. Adjuvant adoptive immunotherapy with IL2 and lymphocytes from tumor-bearing mice: in vitro tumor-stimulated lymphocytes are more effective than LAK cells. Rodolfo M; Salvi C; Bassi C; Rovetta G; Melani C; Colombo MP; Parmiani G Nat Immun Cell Growth Regul; 1991; 10(6):308-19. PubMed ID: 1787836 [TBL] [Abstract][Full Text] [Related]
7. Induction of human lymphokine-activated killer cells by IFN-alpha and IFN-gamma. Ellis TM; McKenzie RS; Simms PE; Helfrich BA; Fisher RI J Immunol; 1989 Dec; 143(12):4282-6. PubMed ID: 2512355 [TBL] [Abstract][Full Text] [Related]
8. Lymphokine-activated killer (LAK) cells. IV. Characterization of murine LAK effector subpopulations. Ballas ZK; Rasmussen W J Immunol; 1990 Jan; 144(1):386-95. PubMed ID: 2104892 [TBL] [Abstract][Full Text] [Related]
9. In vivo migration and tissue localization of highly purified lymphokine-activated killer cells (A-LAK cells) in tumor-bearing rats. Felgar RE; Hiserodt JC Cell Immunol; 1990 Sep; 129(2):288-98. PubMed ID: 2383892 [TBL] [Abstract][Full Text] [Related]
10. Sequential TNF and TGF-beta regulation of expansion and induction of cytotoxicity in long-term cultures of lymphokine-activated killer cells. Koberda J; Przepiorka D; Moser RP; Grimm EE Lymphokine Cytokine Res; 1994 Apr; 13(2):139-45. PubMed ID: 8061115 [TBL] [Abstract][Full Text] [Related]
11. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells. Mulé JJ; Yang J; Shu S; Rosenberg SA J Immunol; 1986 May; 136(10):3899-909. PubMed ID: 2871106 [TBL] [Abstract][Full Text] [Related]
12. Stimulation of IFN-gamma, TNF-alpha, and TNF-beta secretion in IL-2-activated T cells: costimulatory roles for LFA-1, LFA-2, CD44, and CD45 molecules. Chong AS; Boussy IA; Graf LH; Scuderi P Cell Immunol; 1992 Oct; 144(1):69-79. PubMed ID: 1356634 [TBL] [Abstract][Full Text] [Related]
13. High release of tumor necrosis factor alpha, interferon gamma and interleukin-6 by adherent lymphokine-activated killer cells phenotypically derived from T cells. Koberda J; Bergmann L; Mitrou PS; Hoelzer D J Cancer Res Clin Oncol; 1991; 117(5):425-30. PubMed ID: 1909699 [TBL] [Abstract][Full Text] [Related]
14. Recombinant interleukin 2 stimulates in vivo proliferation of adoptively transferred lymphokine-activated killer (LAK) cells. Ettinghausen SE; Lipford EH; Mulé JJ; Rosenberg SA J Immunol; 1985 Nov; 135(5):3623-35. PubMed ID: 3900213 [TBL] [Abstract][Full Text] [Related]
15. Biodistribution and tumor localization of lymphokine-activated killer T cells following different routes of administration into tumor-bearing animals. Kjaergaard J; Hokland ME; Agger R; Skovbo A; Nannmark U; Basse PH Cancer Immunol Immunother; 2000 Jan; 48(10):550-60. PubMed ID: 10630307 [TBL] [Abstract][Full Text] [Related]
16. IL-4-induced lymphokine-activated killer cells. Lytic activity is mediated by phenotypically distinct natural killer-like and T cell-like large granular lymphocytes. Peace DJ; Kern DE; Schultz KR; Greenberg PD; Cheever MA J Immunol; 1988 May; 140(10):3679-85. PubMed ID: 2896213 [TBL] [Abstract][Full Text] [Related]
17. A functional and phenotypic comparison of murine natural killer (NK) cells and lymphokine-activated killer (LAK) cells. Hoskin DW; Stankova J; Anderson SK; Roder JC Int J Cancer; 1989 May; 43(5):940-8. PubMed ID: 2469657 [TBL] [Abstract][Full Text] [Related]
18. Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity. Kawase I; Komuta K; Hara H; Inoue T; Hosoe S; Ikeda T; Shirasaka T; Yokota S; Tanio Y; Masuno T Cancer Res; 1988 Mar; 48(5):1173-9. PubMed ID: 3257715 [TBL] [Abstract][Full Text] [Related]
19. Influence of various cytokines on the induction of lymphokine-activated killer cells. Bergmann L; Weidmann E; Bungert B; Hechler P; Mitrou PS Nat Immun Cell Growth Regul; 1990; 9(4):265-73. PubMed ID: 2120581 [TBL] [Abstract][Full Text] [Related]
20. Induction of murine lymphokine-activated killer cells by recombinant IL-7. Lynch DH; Miller RE J Immunol; 1990 Sep; 145(6):1983-90. PubMed ID: 1975262 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]